SCHEMBL5042459

SCHEMBL5042459

Cc1oc(-c2ccccc2)nc1CCOc1ccc(C=O)c2sccc12

nearest known ligand 0.66

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARG P37231 20/20 0.66
PPARA Q07869 20/20 0.66
PPARD Q03181 6/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30193387 0.94 PPARG (0.58) PPARGPPARAPPARD
SCHEMBL5761883 0.92 PPARG (0.68) PPARGPPARAPPARD
SCHEMBL31095000 0.92 PPARG (0.56) PPARGPPARAPPARD
SCHEMBL30193561 0.91 PPARG (0.57) PPARGPPARAPPARD
SCHEMBL5764287 0.88 PPARG (0.55) PPARGPPARAPPARD
SCHEMBL30193455 0.88 PPARG (0.52) PPARGPPARAPPARD
SCHEMBL482389 0.87 PPARG (0.64) PPARGPPARAPPARD
SCHEMBL482386 0.87 PPARG (0.64) PPARGPPARAPPARD
SCHEMBL482387 0.87 PPARG (0.64) PPARGPPARAPPARD
SCHEMBL5042674 0.86 PPARG (0.63) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670792-B1 PROCESS FOR THE PREPARATION OF CHIRAL PROPIONIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-12-19 EP claimed
US-20070249842-A1 Process for the production of chiral propionic acid derivatives PUENTENER KURT 2007-10-25 US claimed
US-7262303-B2 Process for the production of chiral propionic acid derivatives HOFFMAN-LA ROCHE INC. (US) 2007-08-28 US claimed
JP-2007506800-A 2007-03-22 JP claimed
EP-1670792-A1 PROCESS FOR THE PREPARATION OF CHIRAL PROPIONIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-06-21 EP claimed
WO-2005030764-A1 PROCESS FOR THE PREPARATION OF CHIRAL PROPIONIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-04-07 WO claimed
US-20050070714-A1 Process for the production of chiral propionic acid derivatives HOFFMANN-LA ROCHE INC. 2005-03-31 US claimed
US-7365207-B2 Process for the production of chiral propionic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2008-04-29 US disclosed
US-7365207-B2 Process for the production of chiral propionic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2008-04-29 US disclosed
US-7365207-B2 Process for the production of chiral propionic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2008-04-29 US disclosed
EP-1670792-B1 PROCESS FOR THE PREPARATION OF CHIRAL PROPIONIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-12-19 EP disclosed
US-20070249842-A1 Process for the production of chiral propionic acid derivatives PUENTENER KURT 2007-10-25 US disclosed
US-20070249842-A1 Process for the production of chiral propionic acid derivatives PUENTENER KURT 2007-10-25 US disclosed
US-20050070714-A1 Process for the production of chiral propionic acid derivatives HOFFMANN-LA ROCHE INC. 2005-03-31 US disclosed
WO-2005000844-A1 PROCESS FOR THE PREPARATION OF INSULIN SENSITIZER AND INTERMEDIATE COMPOUND THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2005-01-06 WO disclosed
US-20040267023-A1 Novel process for the preparation of the insulin sensitizer F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2004-12-30 US disclosed
EP-1392295-A1 CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES F. Hoffmann-La Roche AG (CH) 2004-03-03 EP disclosed
US-6642389-B2 For therapy of diabetes HOFFMANN-LA ROCHE INC. 2003-11-04 US disclosed
US-20030055265-A1 Oxazole derivatives HOFFMANN-LA ROCHE INC. 2003-03-20 US disclosed
WO-2002092084-A1 CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070714-A1 Process for the production of chiral propionic acid derivatives HRH4, HRH3, HRH1 PPARG 805/4885PPARA 499/4885PPARD 460/4885
US-20070249842-A1 Process for the production of chiral propionic acid derivatives HRH4, HRH3, HRH1 PPARG 805/4885PPARA 499/4885PPARD 460/4885
US-20040267023-A1 Novel process for the preparation of the insulin sensitizer GPR119, IRS1, INSR PPARG 700/4885PPARA 760/4885PPARD 928/4885
US-20030055265-A1 Oxazole derivatives PPARD, PPARA, PPARG PPARG 3/4885PPARA 2/4885PPARD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.